Advances in molecular targeted therapy of adenocarcinoma of the esophagogastric junction
10.3760/cma.j.issn.1673-4203.2017.02.018
- VernacularTitle:食管胃结合部腺癌分子靶向治疗的研究进展
- Author:
Changsheng PU
;
Zhao LIU
;
Zhi ZHENG
;
Huazheng TANG
;
Jun ZHANG
- Keywords:
Adenocarcinoma of the esophagogastric junction;
Molecular targeted therapy;
Research;
Review
- From:
International Journal of Surgery
2017;44(2):134-138
- CountryChina
- Language:Chinese
-
Abstract:
Adenocarcinoma of the esophagogastric junction is a special type of tumor,not only in the special location,but also in the biological characteristics and clinical manifestations are unique.Surgery is the main treatment,but surgery alone sometimes result in poor prognosis,as a new direction of cancer treatment,Molecular targeting therapy is playing an increasingly important role.Some molecular targets such as vascular endothelial growth factor,hepatocyte growth factor receptor,epidermal growth factor receptor,fibroblast growth factor receptor 2,human epidermal growth factor receptor-2 in the treatment of esophageal gastric adenocarcinoma show a broad prospect.This review summarizes the current status and progress of molecular targeted therapy of adenocarcinoma of esophagogastric junction.
